Evangel Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 99.12%
- Profit Growth -74.29%
- Ebitda 155.14%
- Net Worth 17.47%
- Total Assets 25.66%
About Evangel Pharmaceuticals
Evangel Pharmaceuticals Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 September 2018 (Six years and five months 1 days old ). Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Arpita Saha, Rajesh Saha, and Amit Daloi serve as directors at the Company.
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74990WB2018PTC228161
- Company No.
228161
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Sep 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Evangel Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arpita Saha  | Director | 27-Sep-2018 | Current |
| Rajesh Saha | Director | 27-Sep-2018 | Current |
| Amit Daloi | Director | 27-Sep-2018 | Current |
Financial Performance of Evangel Pharmaceuticals.
Evangel Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 99.12% increase. The company also saw a substantial fall in profitability, with a 74.29% decrease in profit. The company's net worth Soared by an impressive increase of 17.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Evangel Pharmaceuticals?
Unlock access to Evangel Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Evangel Pharmaceuticals?
Evangel Pharmaceuticals has a workforce of 19 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Evangel Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Evangel Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.